LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (Amex:BPA) announced that a new patent has issued covering the formulations used in Elestrin™ (estradiol gel), BioSante’s newly approved treatment for moderate to severe vasomotor symptoms associated with menopause and LibiGel® (testosterone gel), which recently moved into Phase III clinical development for the treatment of female sexual dysfunction. The patent, which issued on April 3, 2007 covering both Elestrin and LibiGel, will expire on June 25, 2022.
